The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments
Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …
Immune cell-mediated features of non-alcoholic steatohepatitis
T Huby, EL Gautier - Nature reviews immunology, 2022 - nature.com
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
[HTML][HTML] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
SM Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021 - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Challenges and opportunities in NASH drug development
SA Harrison, AM Allen, J Dubourg, M Noureddin… - Nature medicine, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …
disease and affects nearly a quarter of the global population. The objective of this work was …
Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH
Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …
[HTML][HTML] A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
PN Newsome, K Buchholtz, K Cusi… - … England Journal of …, 2021 - Mass Medical Soc
Background Nonalcoholic steatohepatitis (NASH) is a common disease that is associated
with increased morbidity and mortality, but treatment options are limited. The efficacy and …
with increased morbidity and mortality, but treatment options are limited. The efficacy and …
Hepatic inflammatory responses in liver fibrosis
Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
Targeting fibrosis: Mechanisms and clinical trials
M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …
dysregulated wound and connective tissue repair response. Multiple organs can develop …